Email updates

Keep up to date with the latest news and content from Arthritis Research & Therapy and BioMed Central.

Review

Green tea polyphenol epigallocatechin 3-gallate in arthritis: progress and promise

Salahuddin Ahmed

Author Affiliations

Department of Pharmacology, 2232 Wolfe Hall, College of Pharmacy, 2801 W. Bancroft Street, Toledo, OH 43606, USA

Arthritis Research & Therapy 2010, 12:208  doi:10.1186/ar2982

Published: 28 April 2010

Abstract

Green tea's active ingredient, epigallocatechin 3-gallate (EGCG), has gained significant attention among scientists and has been one of the leading plant-derived molecules studied for its potential health benefits. In the present review I summarize the findings from some of the most significant preclinical studies with EGCG in arthritic diseases. The review also addresses the limitations of the dose, pharmacokinetics, and bioavailability of EGCG in experimental animals and findings related to the EGCG-drug interaction. Although these findings provide scientific evidence of the anti-rheumatic activity of EGCG, further preclinical studies are warranted before phase clinical trials could be initiated with confidence for patients with joint diseases.